Press release
In safe hands with the GLP checklist
The "Good Laboratory Practice" regulatory mandate (GLP for short) was introduced in 1978 after the FDA (U.S. Food and Drug Administration) had already identified significant deficiencies in toxicological studies in the years preceding. The German Chemicals Act was introduced in an effort to ensure that newly approved drugs for human consumption really are safe and minimize any and all risks.The values of transparency, traceability, assignment of responsibilities, and safekeeping are particularly important in this context. The GLP also checks personal, organizational, and spatial requirements before approving a new drug.
To achieve GLP compliance, specific requirements must be met by the laboratory units (e.g., climate chambers) used in the development of the drugs concerned. Maintenance documents and repair documents must be available to consult when a new drug is being tested. To ensure adherence to all rules and regulations on the unit side during the approval process, BINDER has developed a very helpful checklist for its customers. The checklist guides users through the most important points that are relevant to the compliance of their workflows. Questions include, for example: Is a continuous CO2 supply ensured? Are there back-up chambers available for emergencies? Has a cleaning plan or a maintenance plan been drawn up? All of these questions will help users who are working with a simulation chamber and wish to ensure compliance with the quality guidelines of the GLP regulation.
BINDER temperature, climate, and environmental simulation chambers are the centerpieces of modern laboratories. Designed to meet the highest demands in scientific and industrial fields, they enable the accurate simulation of biological, chemical, and physical environmental conditions. With cutting-edge technology and pioneering innovations, BINDER develops products that provide real added value for the customer. We apply our expertise and feel for the requirements of dynamic, day-to-day work in research facilities to support the widest range of projects and processes in an optimum way. After all, our aim is nothing less than making a contribution to the health, quality of life, and safety of people.
Anne Lenze
PR und Event Specialist
BINDER Central Services GmbH & Co. KG
Im Mittleren Ösch 5
D-78532 Tuttlingen
Phone: +49 7462 / 2005 - 632
Fax: +49 7462 / 2005 - 93 632
E-Mail: Anne.Lenze@binder-world.com
www.binder-world.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release In safe hands with the GLP checklist here
News-ID: 1153087 • Views: …
More Releases from BINDER GmbH

A new innovation from BINDER: The fail-safe function
BINDER incubators are the best on the market. Why is this? There is a simple answer in the first instance: Because they are constructed in as straightforward a way as possible, they are incredibly reliable.
The risk of the cultures inside a BINDER incubator becoming contaminated is reduced to a minimum.
But BINDER customers have high standards and want to know more about the details. This is exactly where the…
More Releases for GLP
GLP Formula Kapseln unterstützt natürlichen Gewichtsverlust und Stoffwechsel …
Hamburg, 31. Juli 2025 - Die Nachfrage nach natürlichen und effektiven Nahrungsergänzungsmitteln wächst stetig. Mit den neuen GLP Formula Capsules wird ab sofort eine neuartige Formel auf dem Markt eingeführt, die den körpereigenen Stoffwechsel unterstützt, das Hungergefühl reduziert und den Gewichtsverlust auf natürliche Weise fördert - ganz ohne künstliche Zusätze oder Chemikalien.
Die Kapseln wurden auf Grundlage aktueller wissenschaftlicher Erkenntnisse rund um das Hormon GLP-1 (Glucagon-like Peptid 1) entwickelt. Dieses Hormon…
GLP-1 Analogues Latest Market Analysis Report 2025
Global Info Research announces the release of the report "Global GLP-1 Analogues Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031". This report provides a detailed overview of the GLP-1 Analogues market scenario, including a thorough analysis of the GLP-1 Analogues market size, sales quantity, average price, revenue, gross margin and market share.The GLP-1 Analogues report provides an in-depth analysis of the competitive landscape, manufacturer's profiles, regional and…
Surging Diabetes Cases Fuel Growth In Glp-1 Receptor Agonist Market: Key Factor …
The GLP-1 Receptor Agonist Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current GLP-1 Receptor Agonist Market Size and Its Estimated Growth Rate?
The market for GLP-1 receptor agonist has seen consistent expansion in the past few years. It is projected to increase…
GLP-1 Market Taming Type 2 Diabetes and Obesity: The Therapeutic Promise of the …
GLP-1 Market Worth $95.4 Mn by 2031 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global GLP-1 Market Size, Share & Trends Analysis Report By Type of Molecule (Biologics and Small Molecules), Active Compound Used (Dulaglutide, Liraglutide, Orforglipron, Retatrutide, Semaglutide, Survodutide, Tirzepatide and Other Active Compounds),
Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist and Short-acting GLP-1 Agonist), Type…
Glucagon Like Peptide-1 (GLP-1) Agonists Market - key players covered:GSK, Sanof …
Los Angeles, United State, –The report titled Global Glucagon Like Peptide-1 (GLP-1) Agonists Market is one of the most comprehensive and important additions to QY Research’s archive of market research studies. It offers detailed research and analysis of key aspects of the global Glucagon Like Peptide-1 (GLP-1) Agonists market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer…
Pharmacelsus' GLP implementation exemplary for European CROs
Scientists of the European Center for Validation of Alternative Methods (ECVAM) attended a GLP workshop at Pharmacelsus GmbH
Saarbrücken, 4. Juni 2009 - Pharmacelsus, a CRO specialized in preclinical test services, obtained GLP-certification covering the complete portfolio in November 2008. The company is not only able to perform accompanying analytical services for clinical studies in addition to its preclinical services, but also decided to share its knowledge on the GLP…